USING TARGETED THERAPIES FOR INFLAMMATORY DERMATOSES
Targeted therapies continue to revolutionize the way we manage chronic inflammatory diseases in dermatology. In contrast to conventional immunosuppressive agents such as methotrexate, cyclosporine, and azathioprine, targeted therapies have the advantage of reducing inflammation to improve cutaneous disease while diminishing the concerns of cumulative end-organ toxicity. This has led to a paradigm shift from approaching disease management from a primarily as-needed basis to the goal of achieving continuous control. Nowhere in dermatology is this transformation more evident than in the treatment of psoriasis
Cutaneous inflammatory conditions such as psoriasis, atopic dermatitis, alopecia areata, vitiligo, and connective tissue diseases often remain a challenge to treat.